Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADMA | US
0.79
4.05%
Healthcare
Biotechnology
30/06/2024
04/10/2024
20.29
19.89
20.58
19.71
ADMA Biologics Inc. a biopharmaceutical company engages in developing manufacturing and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition it operates source plasma collection facilities. The company sells its products through independent distributors drug wholesalers specialty pharmacies and other alternate site providers. ADMA Biologics Inc. was incorporated in 2004 and is headquartered in Ramsey New Jersey.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.4%1 month
59.5%3 months
79.8%6 months
70.8%138.46
28.49
24.00
0.75
0.38
67.53
13.84
-
95.09M
4.73B
4.73B
-
36.57
-
78.30
20.77
3.24
5.49
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.51
Range1M
4.52
Range3M
10.37
Rel. volume
0.61
Price X volume
86.20M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 67.53 | 0.76 | Expensive |
Ent. to Revenue | 13.84 | 3,674.48 | Cheaper |
PE Ratio | 138.46 | 38.01 | Expensive |
Price to Book | 24.00 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 79.83 | 74.67 | Par |
Debt to Equity | 0.75 | -1.82 | Expensive |
Debt to Assets | 0.38 | 0.26 | Expensive |
Market Cap | 4.73B | 3.73B | Market Leader |